Hikma boosted by rise in sales

Hikma Pharmaceuticals said a strong performance in US generics and product launches helped its first-half revenue rise 11 per cent and put it on track for similar growth for the year. The Jordon-based company, which sells off-patent generic drugs under its own brands and in-licensed products across the Middle East and North Africa, and generics in the US, reported sales of $357.7m (£230.1m) and adjusted operating profit of $73.2m, up 20 per cent.